[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100188646":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":24,"responsibleParty":47,"collaborators":50,"id":62,"slug":10,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":10,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Cologne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Emerging fungal infections",null,"Web-based registry of invasive infections by emerging fungi",[13],{"name":14,"affiliation":15,"role":16},"Oliver A. Cornely, Professor","University Hospital of Cologne","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Oliver A Cornely, Prof.","CONTACT","+49 221 478","6494","oliver.cornely@uk-koeln.de",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University Hospital Cologne","RECRUITING","Cologne","North Rhine-Westphalia","50937","Germany",{"type":33,"coordinates":34},"Point",[35,36],6.95,50.93333,{"lat":36,"lon":35},[39,40,44],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},{"name":41,"role":20,"phone":21,"phoneExt":42,"email":43},"Danila Seidel, PhD","97343","danila.seidel@uk-koeln.de",{"name":45,"role":46,"phone":10,"phoneExt":10,"email":10},"Philipp Köhler, MD","SUB_INVESTIGATOR",{"type":16,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Oliver Cornely, MD","Dr. med.",[51,54,56,58,60],{"name":52,"class":53},"Pfizer","INDUSTRY",{"name":55,"class":53},"Basilea Pharmaceutica",{"name":57,"class":53},"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",{"name":59,"class":53},"F2G Biotech GmbH",{"name":61,"class":53},"Matinas Biopharma, Inc","100188646",false,"NCT01731353","FungiScope - A Global Emerging Fungal Infection Registry","FungiScope","Inclusion Criteria:\n\n* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection\n\nExclusion Criteria:\n\n* Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci\n* Endemic fungal infection such as coccidioidomycosis or histoplasmosis\n* Colonisation or other non-invasive infection","ALL",{"count":70,"type":71},1000,"ESTIMATED","OBSERVATIONAL","The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.",[75],"Invasive Fungal Disease",[77,78],"invasive fungal infection","Web-based registry","2023-12-04",{"date":81,"type":82},"2023-12-05","ACTUAL",{"date":84,"type":10},"2003-03",{"date":86,"type":71},"2026-12",{"name":5,"class":6},1]